KOSDAQBiotech & Pharma039840

Dio

₩8,300▲ 0.24%2026-11-18 close
Market Cap
₩111.4B
Turnover
₩400M
Volume
50K
Shares out.
13.4M
PER
—
PBR
0.5×
EPS
-₩492
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

DIO between overseas expansion and its AI pivot

DIO posted record annual revenue for 2025, yet its controlling shareholders' net result swung to a loss in the third quarter of 2026, so whether overseas growth and the AI platform show up in earnings is the central question.

  1. 1

    2025 revenue of KRW 164.1 billion was a record since the company's founding, and operating profit of KRW 10.1 billion turned the year back into profit.

  2. 2

    Overseas sales accounted for more than 80% of revenue, and China sales rose 82.3% to KRW 42.3 billion in 2025.

  3. 3

    Cumulative revenue through the third quarter of 2026 reached KRW 124.6 billion and operating profit KRW 10.6 billion, both up year on year, but third-quarter revenue alone fell 7.6% from a year earlier.

  4. 4

    The controlling shareholders' net result swung to a KRW 21.3 billion loss in the third quarter of 2026, and foreign-currency translation losses were cited as a driver of the cumulative net loss.

  5. 5

    The AI implant platform DIO AX was unveiled in October 2026, and the company's targets are technical verification within the first quarter of 2027 and a full launch by the end of 2027.

02

Business structure

DIO is a digital implant company that manufactures implant systems and supplies them to dental clinics. Its main products are the 11-degree connection implants UNICON and SICON, while PrismX, an 8-degree connection system, is slated for wider overseas supply from late 2026.

The company says it has built more than 1.34 million clinical data records through DIO NAVI, a digital implant solution it has run for more than a decade.

Overseas markets dominate sales: implant export revenue reached KRW 126.7 billion in 2025, up more than KRW 35 billion from the prior year, and overseas sales exceeded 80% of the total.

By country, China was the largest at KRW 42.3 billion in 2025, while Turkey, Portugal and Mexico each topped KRW 10 billion in annual sales. In the first half of 2026, seven core strategic countries generated KRW 54.3 billion, more than 60% of total revenue.

On production, the company expanded the clean room at its Busan plant from 203 square meters to 581 square meters and planned local output at a Sichuan plant to respond to the second round of China's volume-based procurement (VBP), a government program that buys implants in bulk at low prices for public hospitals.

Its customers are dental practitioners, and at an October 2026 event DIO reported about 1,200 dentists and industry participants from 25 countries. The company is also widening its scope from product supply into an AI-based implant care platform.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩41.4B₩4.2B10.0%
2025Q4₩46.7B₩1.4B3.0%
2026Q1₩41.3B₩4.1B10.0%
2026Q2₩44.9B₩4.4B9.8%
2026Q3₩38.3B₩2.1B5.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩131.3B-₩4.4B-₩20.5B−3.4%−12.3%97.5%
2023₩155.8B₩20.9B₩3.3B13.4%1.7%89.1%
2024₩119.6B-₩40.7B-₩41.3B−34.0%−20.2%68.2%
2025₩164.1B₩10.1B-₩1.4B6.2%−0.7%71.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue was KRW 131.3 billion in 2022, KRW 155.8 billion in 2023 (up 18.7%), KRW 119.6 billion in 2024 (down 23.2%) and KRW 164.1 billion in 2025 (up 37.1%), making 2025 the largest year of the 2022 to 2025 span, and one report described it as the company's best result since its founding.

Operating results moved from an operating loss of KRW 4.41 billion in 2022 to operating profit of KRW 20.9 billion in 2023 (a turn to profit), an operating loss of KRW 40.7 billion in 2024 (a turn to loss) and operating profit of KRW 10.1 billion in 2025 (a turn to profit), with operating margins of -3.4%, 13.4%, -34.0% and 6.2%.

Net income attributable to controlling shareholders moved to a KRW 3.31 billion profit in 2023, then to a KRW 41.3 billion net loss in 2024, and the KRW 1.36 billion net loss in 2025 was smaller but still a loss, marking two consecutive loss-making years for 2024 and 2025.

Net income including non-controlling interests was a KRW 1.36 billion loss in 2025, and the gap between positive operating profit and a net loss that year depends on the composition of non-operating items.

The debt-to-equity ratio fell from 97.5% in 2022 to 71.4% in 2025, with total equity of KRW 191.7 billion at year-end 2025, all of it attributable to controlling shareholders, and total liabilities of KRW 136.8 billion.

Operating cash flow improved from negative KRW 1.03 billion in 2022 to KRW 5.44 billion in 2023, KRW 14.7 billion in 2024 and KRW 16.6 billion in 2025.

Quarterly revenue went from KRW 41.4 billion in the third quarter of 2025 to KRW 46.7 billion in the fourth quarter (up 12.7% from the prior quarter), KRW 41.3 billion in the first quarter of 2026 (down 11.6%), KRW 44.9 billion in the second quarter (up 8.8%) and KRW 38.3 billion in the third quarter (down 14.8% from the prior quarter and down 7.6% from a year earlier).

Operating profit went from KRW 4.14 billion in the first quarter of 2026 and KRW 4.41 billion in the second quarter to KRW 2.08 billion in the third quarter (down 49.8% year on year), while controlling shareholders' net income of KRW 9.63 billion in the first quarter gave way to a KRW 21.3 billion net loss in the third quarter.

The sum of controlling shareholders' net losses over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, was KRW 5.09 billion. The company attributed the weaker standalone third quarter to some distribution issues in China.

05

Industry analysis

Seoul Economic Daily reported in April 2026 that DIO recorded its best result since its founding in 2025 while the implant industry was sluggish.

DIO's growth engine is overseas dental markets such as China, Turkey, Portugal and Mexico, and the scarcity of dentists able to perform implant procedures abroad was cited as a condition for market expansion.

China runs a volume-based procurement (VBP) system that buys implants in bulk at low prices, and a second round of VBP could intensify price and volume competition.

DIO outlined a two-track approach in which local production in China targets the low-price segment and Korean-made products target the mid-to-high-price segment. Coverage of the 82.3% rise in China sales in 2025 characterized DIO as having established itself as a major brand in the Chinese market.

On competition, DIO positions its more than 1.34 million clinical data records and its AI platform as points of differentiation. In Europe, UNICON, SICON and PrismX have obtained MDR certification, broadening the basis for supply.

The AI platform aims to cut treatment planning from 30 to 60 minutes to one to two minutes, with the idea of widening the pool of clinicians who can perform implant procedures and thereby lifting implant demand. The company has said it wants to be valued on two pillars, implant manufacturing and its digital platform.

06

Outlook

The company's 2026 revenue target is KRW 200 billion, with a plan to grow more than 30% across seven strategic countries, as reported in March 2026.

Cumulative revenue through the third quarter of 2026 was KRW 124.6 billion, so the distance to the annual target will be visible in the annual report, which includes fourth-quarter 2026 results.

The US subsidiary is targeting more than KRW 10 billion in 2026 sales, and India, Australia and Russia each have a KRW 10 billion target. PrismX is set to expand supply around year-end 2026, centered on Australia, Mexico, the United States, Portugal, India and Turkey.

An April 2026 report said the Sichuan plant in China was planned to start operating in July to take part in quota bidding for China-made products.

The AI platform DIO AX targets completion of technical verification within the first quarter of 2027, with verified functions to be commercialized first as subscription services. A full launch has been set for late 2027, and KRW 100 billion in AI platform revenue by 2030 is the long-term goal.

The company expects wider platform use to also lift sales of existing products such as implants, surgical guides and prosthetic parts. However, the company has said it will present specific platform revenue only after real customer adoption and market validation, so what is public today is targets and timing.

The checkpoints are annual revenue and operating margin in the 2026 annual report, and whether PrismX supply expansion shows up in overseas sales.

07

Valuation

PER
—
PBR
0.5×
ROE
-2.7%
EPS
-₩492
BPS
₩16,135
Dividend per share
₩0

The price-to-book ratio sits below 1x, which means the shares trade at a price low relative to book equity. Total equity of KRW 191.7 billion at year-end 2025 equals the equity attributable to controlling shareholders, so the entire net asset base belongs to controlling shareholders.

Because the sum of controlling shareholders' net losses over the last four quarters was KRW 5.09 billion, an earnings-based price-to-earnings ratio is not calculated. Dividend-based valuation is hard to apply, so the valuation hinges on the path of earnings recovery.

Operating profit has swung widely, from a turn to profit in 2023 to a turn to loss in 2024, so the earnings base used for multiple analysis changes from year to year. Operating margin recovered to 6.2% in 2025 and the debt-to-equity ratio stood at 71.4%.

The low price-to-book level and the absence of an earnings-based multiple should be read together, and the annual earnings in the 2026 annual report will make the basis for multiple analysis clearer.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Overseas-led revenue growth

2025 revenue rose 37.1% from the prior year, and overseas sales exceeded 80% of the total. China sales grew 82.3%, while Turkey, Portugal and Mexico each passed KRW 10 billion in annual sales. In the first half of 2026, seven strategic countries generated KRW 54.3 billion, more than 60% of total revenue. MDR certification for UNICON, SICON and PrismX broadened the basis for entry into Europe.

A profit structure that turned from losses to gains

Operating results moved from an operating loss of KRW 40.7 billion in 2024 to operating profit of KRW 10.1 billion in 2025, with an operating margin of 6.2%. Operating cash flow improved sharply from negative KRW 1.03 billion in 2022 to KRW 16.6 billion in 2025.

The debt-to-equity ratio fell from 97.5% in 2022 to 71.4% in 2025, and total liabilities at year-end 2025 were KRW 136.8 billion.

AI platform and clinical data assets

More than 1.34 million clinical data records accumulated through DIO NAVI are presented as the foundation for AI model development. DIO unveiled DIO AX, co-developed with LG CNS, in October 2026, and named subscription fees and higher sales of existing implants as revenue drivers. The company has set a target of KRW 100 billion in AI platform revenue by 2030.

09

Bear factors

Slower standalone third quarter

Third-quarter 2026 revenue was KRW 38.3 billion, down 14.8% from the prior quarter and down 7.6% from a year earlier. Operating profit of KRW 2.08 billion fell 49.8% year on year. The company said some distribution issues in China affected third-quarter results and that it had resolved them promptly.

Swing to net loss and currency exposure

Controlling shareholders' net result swung to a KRW 21.3 billion loss in the third quarter of 2026. Foreign-currency translation losses on intercompany bonds denominated in foreign currency at overseas sales subsidiaries were cited as a reason for the cumulative net loss. The sum of controlling shareholders' net losses over the last four quarters was KRW 5.09 billion.

Overseas dependence and price pressure

With overseas sales above 80% of revenue, distribution problems in a single country or currency moves can feed directly into results. In China, the VBP system could push implant prices lower, which could intensify competition among China-made products. The specific revenue scale of the AI platform has not yet been disclosed.

10

Risk factors

China pricing and distribution risk

China runs a volume-based procurement system for public hospitals, and a second round is seen as a source of price pressure. In the third quarter of 2026, some distribution issues in China weighed on quarterly revenue, so channel management remains a challenge. Local production at the Sichuan plant has been presented as central to the bidding strategy.

Currency and translation gain-loss risk

The company explained that its foreign-currency intercompany bonds at overseas sales subsidiaries, valued at period-end exchange rates, generated losses. With more than 80% of sales overseas, currency moves can widen volatility in non-operating items and net income. Foreign-currency translation losses were reported as a reason for the cumulative net loss.

AI platform commercialization risk

The target for completing technical verification of DIO AX is within the first quarter of 2027, and a full launch has been set for late 2027. The company has said it will disclose specific platform revenue only after real customer adoption and market validation. If the schedule slips, the timeline for the KRW 100 billion revenue goal for 2030 could also shift.

11

What to watch next

  1. Year-end 2026

    The next checkpoints are whether PrismX supply expansion in key markets actually begins and whether China sales keep growing in the fourth quarter.

  2. End of March 2027

    The 2026 annual report is typically due within 90 days of fiscal year-end, and it will show annual revenue against the KRW 200 billion target, operating margin and controlling shareholders' net result.

  3. Within Q1 2027

    This is the target window for completing DIO AX technical verification, and the result will indicate how far the subscription service commercialization timeline is advancing.

  4. End of 2027

    This is the planned full launch of DIO AX, and whether subscription revenue is disclosed for the first time is the key point to watch.

  5. 2030

    This is the point at which the long-term goal of KRW 100 billion in AI platform revenue can be checked against actual results.

12

Overall view

DIO moved from an operating loss structure to profit in 2025, with revenue of KRW 164.1 billion and operating profit of KRW 10.1 billion, and overseas sales above 80% define its growth profile.

Cumulative revenue and operating profit through the third quarter of 2026 rose year on year, but standalone third-quarter revenue declined. The controlling shareholders' net result turned to a KRW 21.3 billion loss in the third quarter, with currency translation losses and China distribution issues cited as background.

Strengths include the broader overseas lineup led by PrismX and MDR certification, China sales growth and an AI platform built on more than 1.34 million clinical records.

Weaknesses include quarterly volatility, China price pressure and currency exposure from heavy overseas dependence, and the absence of disclosed AI platform revenue. Both sets of factors coexist, and the sum of controlling shareholders' net losses over the last four quarters was KRW 5.09 billion.

The next checkpoints are annual revenue against the KRW 200 billion target in the 2026 annual report, whether PrismX expansion lands at year-end, and the outcome of DIO AX technical verification in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. etoday.co.kr
  2. newsflix.co.kr
  3. pharm.edaily.co.kr
  4. dentalarchive.tv
  5. m.sedaily.com
  6. etoday.co.kr
  7. supple.kr
  8. m.news.nate.com
  9. hankyung.com
  10. lawissue.co.kr
  11. tradingkey.com
  12. tradingkey.com
  13. etoday.co.kr
  14. stocktitan.net
  15. stocktitan.net
  16. datatooza.com
  17. globenewswire.com
  18. investor.diodes.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis